Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ym Biosciences Inc.
Headquarters: Mississauga, ON, Canada
Website: N/A
Year Founded: 1994
Status: Acquired
BioCentury | Apr 19, 2023
Product Development
Gilead’s next steps in oncology
Ambitious top-10 goal in cancer by 2030, with BD focus on early-stage assets that add mechanisms to pipeline
BioCentury | Apr 13, 2022
Deals
On heels of catalyst, Sierra picks GSK’s $1.9B takeout over ex-U.S. partnership
After signaling that an ex-U.S. deal was in the works, Sierra chose the M&A route, giving GSK global rights to a late-stage myelofibrosis candidate
BioCentury | Jan 27, 2022
Deals
Jan. 26 Quick Takes: Kyverna’s autoimmune cell therapies get lift from $85M series B
Plus clinical hold for Cortexyme’s lead Alzheimer’s therapy; PureTech’s Akili goes public via SPAC; Adlai, Biotime deal; and more
BioCentury | Aug 26, 2020
Deals
Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues
Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s
BioCentury | Nov 16, 2016
Clinical News
Mixed Phase III results for Gilead's momelotinib in myelofibrosis
BioCentury | Jan 5, 2015
Finance
Back for more
Tallying Vivo's recent exits as VC raises $428M for eighth fund
Items per page:
1 - 10 of 182